Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8232 for albuminuria in diabetic kidney disease
NCT02358096Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in diabetic kidney disease (DKD) comparing ASP8232 with Placebo (2 arms). Primary endpoint: Urinary Albumin to Creatinine Ratio at 12 weeks. Started Mar 2015; status: completed.
02
Drugs
ASP8232
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT02358096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358096.